What is the fair value of GH Research PLC (NASDAQ-GHRS) stock?

The current fair value estimate for GH Research PLC (NASDAQ-GHRS) is $34.48. This implies an estimated upside of 22.4% versus the current market price.

Is GH Research PLC (NASDAQ-GHRS) undervalued or overvalued?

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 22.4% versus the current market price.

What is the analyst price target for NASDAQ-GHRS stock?

The available analyst price target for GH Research PLC (NASDAQ-GHRS) is $39.50. The analyst target implies estimated upside of 40.2%.

How is the financial health of GH Research PLC?

The current financial health read for GH Research PLC (NASDAQ-GHRS) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is GH Research PLC's next earnings date?

The next earnings date currently listed for GH Research PLC (NASDAQ-GHRS) is August 26, 2026.

Does GH Research PLC (NASDAQ-GHRS) pay dividends?

Based on the current data, dividend yield is 0.0%.

What is the P/E ratio for GH Research PLC (NASDAQ-GHRS)?

The current P/E ratio listed for GH Research PLC (NASDAQ-GHRS) is -34.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

What is the market capitalization of GH Research PLC?

The current market capitalization listed for GH Research PLC is 1.889 B.

What is the enterprise value of GH Research PLC?

The current enterprise value listed for GH Research PLC is 1.664 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for GH Research PLC?

The ticker symbol for GH Research PLC is NASDAQ-GHRS, and the stock is listed on NASDAQ.

Where is GH Research PLC (NASDAQ-GHRS) listed?

GH Research PLC (NASDAQ-GHRS) is listed on NASDAQ.

What is the debt-to-total-capital ratio for GH Research PLC?

The current debt-to-total-capital ratio listed for GH Research PLC is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for GH Research PLC?

The free float listed for GH Research PLC is 43.1%. Free float helps investors understand how much of the share base is available for public trading.

GH Research PLC (GHRS) Fair Value & Stock Analysis

GH Research PLC (GHRS)

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for depression and related psychiatric conditions. Its lead candidate, GH001, is an inhaled mebufotenin program being studied in a Phase 2b trial for treatment-resistant depression, along with Phase 2a trials in bipolar II disorder and postpartum depression. The company is also advancing GH002, an intravenous mebufotenin candidate in Phase 1 clinical pharmacology testing in healthy volunteers, with research aimed at psychiatric and neurological disorders. GH Research PLC was founded in 2018 and is based in Dublin, Ireland.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Upcoming Dividend Ex-Date	Dividend Payment Date	Upcoming Dividend	Dividend Yield	Next Earnings Date	P/E Ratio	Price-to-Book Ratio	Price-to-Sales Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Payout Ratio	Free Cash Flow / Net Income
NASDAQ-GHRS	$34.48	22.4% Upside	Undervalued	$39.50	40.2% Upside	Undervalued	Good	—	—	—	0.0%	August 26, 2026	-34.2x	7.3x	—	1.889 B	1.664 B	0.0%	43.1%	29.0	—	81.2%